
Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC
Combining lurbinectedin (Zepzelca) with pembrolizumab (Keytruda) elicited significant activity in a small cohort of patients with relapsed small cell lung cancer (SCLC), according to data from the phase 1/2 LUPER study (NCT04358237) published in …